Red Teaming in Hyderabad · Pharma & US-Healthcare GCC
MITRE ATT&CK-aligned red-team engagements for Hyderabad pharma R&D, clinical-trial SaaS and US-healthcare GCCs — regulated-data-exfil objectives.
What is Red Team in Hyderabad?
Red teaming is a goal-based, full-scope adversary simulation that tests people, process, and technology together — using phishing, physical, and assumed-breach entry to reach a defined objective such as domain admin or a payment system. In Hyderabad, Macksofy scopes and delivers the engagement to local regulators, procurement, and timelines — with proof-of-concept findings, board-ready reporting, and a remediation retest.
How does a Macksofy Red Team engagement run in Hyderabad?
Hyderabad red-teaming has a sharply defined buyer profile no other Indian metro matches. Top-5 generics with Shameerpet R&D campuses, Patancheru API plants and Bachupally formulation belts run annual adversary-simulation engagements to evidence that motivated threat actors cannot corrupt clinical-trial data integrity, exfiltrate IP, or compromise GMP-validated systems ahead of the next FDA / EMA / DCGI inspection. Clinical-trial SaaS operators in Genome Valley run red-team engagements to satisfy sponsor (US pharma giant) cyber-resilience expectations. US-healthcare GCCs in Gachibowli and Q City run red-team engagements aligned to the US parent's HIPAA / HITRUST adversary-simulation cadence. Macksofy's Hyderabad red-team bench is engineered for these three sub-segments with separate emulation profiles.
Pharma threat-actor emulation is the headline capability. Real adversaries active in the pharma sector — APT41 (intellectual-property exfiltration), Lazarus / DarkSide (financial-motivation against pharma), MuddyWater (regional state-adjacent against critical infrastructure), and FIN-style actors targeting reimbursement / payer-data flows — are emulated per the customer's threat model. The objective is calibrated to the customer's specific risk. For a Top-5 generics with US-bound clinical-trial data, the objective is typically 'exfiltrate the eCRF / EDC clinical-trial-data pre-FDA-PAI without QA detection by D+15'. For a CRO, the objective is typically 'corrupt the eTMF audit-trail integrity without sponsor or regulator detection'. The plan is signed by the CTO, the CISO and the QA director before the operations team is informed (or, in a blind engagement, kept blind).
Initial-access vectors in pharma red-team engagements run lanes that other industries do not. Vendor-portal compromise against the CDS / LIMS / eTMF vendor support portal (high-yield because the vendor portal is often less hardened than the customer environment, and the vendor's access to the customer environment is privileged). Spear-phish against the QA director's office and the regulatory-affairs function (the lure calibrated to FDA / EMA / DCGI inspection cycle news). Physical access via tailgating a Genome Valley R&D campus lobby or QC lab cafeteria. Public-facing exploit chains against the customer's regulatory-affairs submission portal or sponsor-collaboration platform.
Post-exploitation in pharma red-team engagements traverses ALL three estate types — corporate IT, R&D network, and QC lab network. The R&D network is the highest-value target (clinical-trial data, IP, sponsor-side data) but also the most regulated (validation-state preservation, ALCOA+ contemporaneity). The QC lab network houses lab-instrument workstations integrated into LIMS / CDS — these are valid lateral-movement footholds and the engagement's controlled-stop is at the data-integrity boundary (no actual tampering, evidence via screenshot + hash). The corporate IT network is the access lane to both R&D and QC lab segments and where the AD privilege paths typically run.
Clinical-trial SaaS red-team engagements have a different shape. The customer-facing platform (sponsor-side or CRO-side) is the target surface. Multi-tenant sponsor-isolation, eTMF audit-trail integrity, EDC clinical-trial-data exfiltration, and (where applicable) the AI-investigator-assistant LLM surface. Adversary emulation is typically calibrated to sponsor-cyber-resilience expectations — most US pharma sponsors require their clinical-trial SaaS vendors to run an annual red-team with sponsor-data-exfil objectives. The deliverable doubles as the sponsor's annual cyber-resilience attestation.
US-healthcare GCC red-team engagements align to US-parent adversary-simulation cadence — typically HITRUST CSF-aligned, parent-specific (Optum, UnitedHealth, Cigna, CVS Health each have their own internal red-team standards), and reported in the format the parent's compliance function expects. The engagement closes the parent's annual HIPAA penetration-test attestation and the HITRUST CSF e-3 control evidence. Onsite legs at Gachibowli or Q City include a virtual closing call with the US parent's regional CISO and (where applicable) the parent's adversary-emulation lead.
Procurement reality matters. Pharma red-team engagements close through the CTO, the CISO and the QA director, often with the head of regulatory-affairs copied because of inspection-cycle alignment. Engagement letters include trespass-and-deception waivers, QA-witness scheduling for any lab-instrument scope, controlled-stop at the data-integrity boundary acknowledgement, and the no-state-alteration acknowledgement standard for GMP-validated systems. Clinical-trial SaaS engagements close through the CTO and head of customer security with the sponsor-side compliance function copied for sponsor-data-exfil objectives. US-healthcare GCC engagements close through the Indian CISO with the US parent's regional CISO and parent's adversary-emulation lead copied.
Onsite cadence — HITEC City regional hub means two-hour onsite SLA across Madhapur, Gachibowli, Banjara Hills, Kondapur and Genome Valley. Patancheru / Bachupally / Shameerpet are 60-90 minutes from the hub. Pharma red-team engagements typically run 6-8 weeks — 1 week threat-model and recon, 4-5 weeks active operations across all three estate types, 1-2 weeks reporting and inspection-defence rehearsal. Clinical-trial SaaS and US-healthcare GCC engagements run 5-6 weeks. All engagements include a paired detection-engineering analyst with the customer's blue-team for the closing week.
Five phases. Hyderabad timeline.
Every Macksofy Red Team engagement in Hyderabad runs through the same phased protocol — adapted to Hyderabad-specific procurement, regulator and delivery realities.
- Phase 01
Threat Model & Plan
Week 1- Joint kickoff with CTO, CISO and QA director; emulation plan calibrated to pharma threat model
- Threat-actor selection — APT41 / Lazarus / DarkSide / MuddyWater / FIN-style profiles per customer risk
- Engagement letter — trespass-and-deception, QA-witness scheduling, no-state-alteration for GMP-validated, controlled-stop at data-integrity boundary
- Inspection-calendar alignment — FDA / EMA / DCGI dates pinned against finding-closure milestones
- Phase 02
Recon & Initial Access
Weeks 1–2- OSINT against QA director's office, regulatory-affairs function, sponsor / CRO partner ecosystem
- Vendor-portal compromise on CDS / LIMS / eTMF vendor support portal
- Spear-phish lure calibrated to FDA / EMA / DCGI inspection cycle news
- Genome Valley / Madhapur tower-lobby tailgate or QC lab cafeteria USB-drop where in scope
- Phase 03
Three-Estate Traversal
Weeks 2–4- Corporate IT — ADCS / Kerberos / SCCM privilege escalation on the on-premises forest
- R&D network — sponsor-side data exfiltration objective, eCRF / EDC clinical-trial-data lateral movement
- QC lab network — lab-instrument workstation lateral, LIMS data-server access, controlled-stop at data-integrity
- Clinical-trial SaaS — multi-tenant sponsor-isolation, eTMF audit-trail, sponsor-data-exfil objective
- Phase 04
Objective Execution
Weeks 4–5- Controlled-stop at the data-integrity boundary; evidence via screenshot + hash; no actual tampering
- QA-witnessed walk-through for any GMP-validated system in the kill chain
- DPDP §16 cross-border-data-flow evidence per path exercised
- HITRUST CSF e-3 + HIPAA §164.308-312 evidence for US-healthcare GCC engagements
- Phase 05
Inspection-Defence & Detection Content
Weeks 5–6- QA-readable executive summary in 21 CFR Part 11 / GMP Annex 11 / ALCOA+ language
- Inspection-defence rehearsal pack — likely inspector / sponsor questions per finding category
- Joint SOC tabletop with operator-console kill-chain replay
- Paired detection content (Sigma / SPL / KQL) for the customer's SIEM — 8-15 rules per engagement
- Phase 01Week 1
Threat Model & Plan
- Joint kickoff with CTO, CISO and QA director; emulation plan calibrated to pharma threat model
- Threat-actor selection — APT41 / Lazarus / DarkSide / MuddyWater / FIN-style profiles per customer risk
- Engagement letter — trespass-and-deception, QA-witness scheduling, no-state-alteration for GMP-validated, controlled-stop at data-integrity boundary
- Inspection-calendar alignment — FDA / EMA / DCGI dates pinned against finding-closure milestones
- Phase 02Weeks 1–2
Recon & Initial Access
- OSINT against QA director's office, regulatory-affairs function, sponsor / CRO partner ecosystem
- Vendor-portal compromise on CDS / LIMS / eTMF vendor support portal
- Spear-phish lure calibrated to FDA / EMA / DCGI inspection cycle news
- Genome Valley / Madhapur tower-lobby tailgate or QC lab cafeteria USB-drop where in scope
- Phase 03Weeks 2–4
Three-Estate Traversal
- Corporate IT — ADCS / Kerberos / SCCM privilege escalation on the on-premises forest
- R&D network — sponsor-side data exfiltration objective, eCRF / EDC clinical-trial-data lateral movement
- QC lab network — lab-instrument workstation lateral, LIMS data-server access, controlled-stop at data-integrity
- Clinical-trial SaaS — multi-tenant sponsor-isolation, eTMF audit-trail, sponsor-data-exfil objective
- Phase 04Weeks 4–5
Objective Execution
- Controlled-stop at the data-integrity boundary; evidence via screenshot + hash; no actual tampering
- QA-witnessed walk-through for any GMP-validated system in the kill chain
- DPDP §16 cross-border-data-flow evidence per path exercised
- HITRUST CSF e-3 + HIPAA §164.308-312 evidence for US-healthcare GCC engagements
- Phase 05Weeks 5–6
Inspection-Defence & Detection Content
- QA-readable executive summary in 21 CFR Part 11 / GMP Annex 11 / ALCOA+ language
- Inspection-defence rehearsal pack — likely inspector / sponsor questions per finding category
- Joint SOC tabletop with operator-console kill-chain replay
- Paired detection content (Sigma / SPL / KQL) for the customer's SIEM — 8-15 rules per engagement
Which Hyderabad sectors does Macksofy deliver Red Team for?
Pharma R&D & generics
Top-5 generics with Shameerpet R&D, Patancheru API plants and Bachupally formulations — three-estate red-team with QA-witnessed lab-instrument scope.
CROs & clinical-trial sites
Genome Valley CROs — eTMF audit-trail integrity and sponsor-data-exfil objectives with DPDP §16 evidence.
Clinical-trial SaaS
eTMF / EDC / clinical-trial-management SaaS operators — multi-tenant sponsor-isolation red-team with annual sponsor-cyber-resilience attestation.
US-healthcare GCCs
Gachibowli and Q City BPO/GCC operations on US PHI — HITRUST CSF e-3 + HIPAA evidence with US-parent virtual readout.
Pharma customer portals
Top-5 generics' patient-engagement / eDetailing portal red-team — DPDP + (where applicable) HIPAA overlay.
Healthcare AI products
Healthcare AI products — LLM-application adversary emulation with prompt-injection, training-data exfil and patient-impersonation objectives.
The Hyderabad deliverable pack.
Every Hyderabad Red Team engagement closes with the pack below — regulator-ready evidence, technical detail and board-readable summaries.
- Threat-actor emulation plan signed by CTO + CISO + QA director at kickoff
- Kill-chain narrative with MITRE ATT&CK technique-by-technique reconciliation
- Three-estate traversal memo (corporate IT, R&D network, QC lab network)
- QA-witnessed walk-through evidence for any GMP-validated system in the kill chain
- QA-readable executive summary in 21 CFR Part 11 / GMP Annex 11 / ALCOA+ language
- Inspection-defence rehearsal pack with likely FDA / EMA / DCGI / sponsor questions
- HITRUST CSF e-3 + HIPAA §164.308-312 evidence for US-healthcare GCC engagements
- 8-15 production-ready detection rules (Sigma / SPL / KQL) shipped to the customer's SIEM
A Hyderabad Red Team case study.
8-week red-team — APT41-style threat-actor emulation; objective: exfiltrate eCRF clinical-trial data from the R&D network pre-FDA-Pre-Approval-Inspection without QA detection by D+15; three-estate scope (corporate IT in Madhapur, R&D network in Shameerpet, QC lab network in Bachupally with lab-instrument workstation lateral); QA director + IT head + CISO white-cell; QA-witnessed lab-instrument walk-throughs
Objective met at D+12 via vendor-portal compromise on the CDS vendor's support portal → QC lab workstation lateral → R&D network data-server access → eCRF clinical-trial-data exfil-controlled-stop with evidence-via-screenshot-plus-hash; two ALCOA+ contemporaneity exposures and one eTMF audit-trail disable-path closed pre-FDA-PAI; 11 paired detection rules adopted by the SOC inside two weeks; FDA PAI subsequently cleared with zero non-conformities; sponsor cyber-resilience attestation accepted by three US pharma sponsors for the next 12 months.
Empanelled by CERT-In. Accredited by EC-Council.
“We've worked with three Big 4 firms before Macksofy. None found what their team did in our payments stack. The most actionable report we've received in a decade.”
“The CHFI training Macksofy delivered for our cyber cell raised investigation quality measurably. Practical, India-context-aware, and respectful of our operational realities.”
“Came in with zero security background. 5 weeks later I was running Burp Suite and Metasploit confidently. Cleared CEH on the first attempt.”
What do Hyderabad buyers ask before signing?
Other Macksofy engagements in Hyderabad.
Same engagement, other Macksofy metros.
Get a fixed-price proposal in 48 hours.
Tell us about your security need — pentest, audit, training or a wider engagement. A senior consultant will reply within a few business hours.
- CERT-In Empanelled
- EC-Council ATC
- Thousands of professionals trained
- India + UAE engagements
